Table of Contents Author Guidelines Submit a Manuscript
Advances in Urology
Volume 2012 (2012), Article ID 181987, 13 pages
http://dx.doi.org/10.1155/2012/181987
Review Article

Bladder Cancer Immunotherapy: BCG and Beyond

Department of Urology, University of Iowa, 375 Newton Road, 3204 MERF, Iowa City, IA 52242, USA

Received 16 March 2012; Accepted 11 May 2012

Academic Editor: Trinity J. Bivalacqua

Copyright © 2012 Eric J. Askeland et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citations to this Article [51 citations]

The following is the list of published articles that have cited the current article.

  • Gopitkumar Shah, Guangjian Zhang, Fanghong Chen, YanLi Cao, Balaraman Kalyanaraman, and William See, “Loss of Bacillus Calmette-Guérin Viability Adversely Affects the Direct Response of Urothelial Carcinoma Cells to Bacillus Calmette-Guérin Exposure,” The Journal of Urology, 2013. View at Publisher · View at Google Scholar
  • Scott Palmer, Sergei G. Sokolovski, Edik Rafailov, and Ghulam Nabi, “Technologic Developments in the Field of Photonics for the Detection of Urinary Bladder Cancer,” Clinical Genitourinary Cancer, 2013. View at Publisher · View at Google Scholar
  • Luís Lima, Daniela Oliveira, Ana Tavares, Teresina Amaro, Ricardo Cruz, Maria J. Oliveira, José A. Ferreira, and Lúcio Santos, “The predominance of M2-polarized macrophages in the stroma of low-hypoxic bladder tumors is associated with BCG immunotherapy failure,” Urologic Oncology: Seminars and Original Investigations, 2013. View at Publisher · View at Google Scholar
  • Regina Arantes-Rodrigues, Rosário Pinto-Leite, Lio Fidalgo-Gonçalves, Carlos Palmeira, Lúcio Santos, Aura Colaço, and Paula Oliveira, “Synergistic Effect between Cisplatin and Sunitinib Malate on Human Urinary Bladder-Cancer Cell Lines,” BioMed Research International, vol. 2013, pp. 1–11, 2013. View at Publisher · View at Google Scholar
  • Jose Alexandre Ferreira, Celso A. Reis, Mylene Carrascal, Paulo F. Seuerino, Andreia Almeida, Rui Vitorino, Paula A. Videira, Luis Lima, Sofia Pereira, Lucio Lara Santos, Mariana Silva, Elisabete Fernandes, Ceu Costa, Teresina Amaro, Maria J. Oliveira, Fabio Dall'Olio, and Francisco Amado, “Overexpression of tumour-associated carbohydrate antigen sialyl-Tn in advanced bladder tumours,” Molecular Oncology, vol. 7, no. 3, pp. 719–731, 2013. View at Publisher · View at Google Scholar
  • Yonghua Wang, Meng Yang, Qinchao Yu, Lun Yu, Shixiu Shao, and Xinsheng Wang, “Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies,” Expert Review of Anticancer Therapy, pp. 1–9, 2014. View at Publisher · View at Google Scholar
  • Jessica R. Newman, Lisa A. Clough, and Fernando Merino, “Mycobacterium bovis Osteomyelitis of the Thoracic Spine Mimicking a Metastatic Lytic Lesion in a Patient Exposed to Intravesicular Bacille Calmette-Guérin Treatment,” Urology Case Reports, vol. 2, no. 4, pp. 142–144, 2014. View at Publisher · View at Google Scholar
  • Evan Gomes-Giacoia, Makito Miyake, Steve Goodison, Aravindhan Sriharan, Ge Zhang, Lijing You, Jack O. Egan, Peter R. Rhode, Alexander S. Parker, Karl X. Chai, Hing C. Wong, and Charles J. Rosser, “Intravesical ALT-803 and BCG Treatment Reduces Tumor Burden in a Carcinogen Induced Bladder Cancer Rat Model; a Role for Cytokine Production and NK Cell Expansion,” Plos One, vol. 9, no. 6, 2014. View at Publisher · View at Google Scholar
  • Xiaoxuan Liu, Alexander C Dowell, Prashant Patel, Richard P Viney, Michael C Foster, Emilio Porfiri, Nicholas D James, and Richard T Bryan, “Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette–Guérin,” Future Oncology, vol. 10, no. 8, pp. 1443–1456, 2014. View at Publisher · View at Google Scholar
  • Ronald Rooke, “Can Calcium Signaling be harnessed for cancer immunotherapy?,” Biochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2014. View at Publisher · View at Google Scholar
  • J.C. Santos, N. Rolim, T. Rodrigues, F. Lopes, R.L. Mota, A. Covita, M.J. Soares, P. Monteiro, A. Canhoto, R. Nogueira, and H. Monteiro, “Terapêutica intravesical com bacilo de Calmette-Guérin no tratamento do carcinoma da bexiga / o que sabemos até agora,” Acta Urológica Portuguesa, vol. 31, no. 3, pp. 75–81, 2014. View at Publisher · View at Google Scholar
  • Gopitkumar Shah, Jacek Zielonka, Fanghong Chen, Guangjian Zhang, Yanli Cao, Balaraman Kalyanaraman, and William See, “H2O2 Generation by bacillus Calmette-Guerin Induces the Cellular Oxidative Stress Response Required for bacillus Calmette-Guerin Direct Effects on Urothelial Carcinoma Biology,” Journal of Urology, vol. 192, no. 4, pp. 1238–1248, 2014. View at Publisher · View at Google Scholar
  • Naim B. Farah, Rami Ghanem, and Mahmoud Amr, “Treatment efficacy and tolerability of intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and maintenance protocol in high grade and recurrent low grade non-muscle invasive bladder cancer (NMIBC),” Bmc Urology, vol. 14, 2014. View at Publisher · View at Google Scholar
  • Linda C Sandin, Thomas H Tötterman, and Sara M Mangsbo, “Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer,” OncoImmunology, vol. 3, no. 1, pp. e27400, 2014. View at Publisher · View at Google Scholar
  • Jun Hyun Kim, Su Hyun Ahn, Jeong Min Kim, and So-Yoon Lee, “Metachronous Adenoid Cystic Carcinoma in the Peripheral Lung and at Base of the Tongue,” Clinical and Experimental Otorhinolaryngology, vol. 7, no. 3, pp. 232, 2014. View at Publisher · View at Google Scholar
  • Durán, Marcato, and Fávaro, “Cisplatin properties in a nanobiotechnological approach to cancer: A mini-review,” Current Cancer Drug Targets, vol. 14, no. 5, pp. 458–476, 2014. View at Publisher · View at Google Scholar
  • Guantian Yang, Zengjun Wang, Wei Wang, Xiang Zhou, Xiangnong Hu, and Jianjun Yang, “Anticancer activity of Luteolin and its synergism effect with BCG on human bladder cancer cell line BIU-87,” Journal of Central South University (Medical Sciences), vol. 39, no. 4, pp. 371–378, 2014. View at Publisher · View at Google Scholar
  • Voshaar, Kambartel, Stais, and Yildirim, “Severe disseminated mycobacterium bovis BCG infection as a consequence of intravesical BCG therapy: Diagnostic challenges and therapeutic options,” Pneumologie, vol. 68, no. 7, pp. 488–491, 2014. View at Publisher · View at Google Scholar
  • Yuan-qiang Zheng, Youssef W. Naguib, Yixuan Dong, Yan-chun Shi, Shorgan Bou, and Zhengrong Cui, “Applications of bacillus Calmette-Guerin and recombinant bacillus Calmette-Guerin in vaccine development and tumor immunotherapy,” Expert Review Of Vaccines, vol. 14, no. 9, pp. 1255–1275, 2015. View at Publisher · View at Google Scholar
  • Erlin Sun, Xiaodong Fan, Lining Wang, Mingde Lei, Xiaodong Zhou, Chunyu Liu, Bingxin Lu, Xuewu Nian, Yan Sun, and Ruifa Han, “Recombinant hIFN-alpha 2b-BCG inhibits tumor growth in a mouse model of bladder cancer,” Oncology Reports, vol. 34, no. 1, pp. 183–194, 2015. View at Publisher · View at Google Scholar
  • Luís Lima, Daniela Oliveira, José A. Ferreira, Ana Tavares, Ricardo Cruz, Rui Medeiros, and Lúcio Santos, “The role of functional polymorphisms in immune response genes as biomarkers of bacille Calmette-Guérin (BCG) immunotherapy outcome in bladder cancer: establishment of a predictive profile in a Southern Europe population,” BJU International, 2015. View at Publisher · View at Google Scholar
  • Kenan Izgi, Banu Iskender, Cagri Sakalar, Aslihan Arslanhan, Berkay Saraymen, and Halit Canatan, “Evaluation of two different adjuvants with immunogenic uroplakin 3A-derived peptide for their ability to evoke an immune response in mice,” European Cytokine Network, vol. 26, no. 2, pp. 46–56, 2015. View at Publisher · View at Google Scholar
  • K. R. Begnini, J. H. Buss, T. Collares, and F. K. Seixas, “Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer,” Applied Microbiology and Biotechnology, 2015. View at Publisher · View at Google Scholar
  • Sean G. Smith, Bhanu prasanth Koppolu, Sruthi Ravindranathan, Samantha L. Kurtz, Lirong Yang, Matthew D. Katz, and David A. Zaharoff, “Intravesical chitosan/interleukin-12 immunotherapy induces tumor-specific systemic immunity against murine bladder cancer,” Cancer Immunology, Immunotherapy, 2015. View at Publisher · View at Google Scholar
  • Robert T. Jones, Kenneth M. Felsenstein, and Dan Theodorescu, “Pharmacogenomics,” Urologic Clinics of North America, 2015. View at Publisher · View at Google Scholar
  • Diego Stéfani T. Martinez, Ana C. M. de Moraes, Nelson Durán, Camila P. Silveira, Marcela Durán, Mateus B. Simões, Oswaldo L. Alves, and Wagner J. Fávaro, “Graphene oxide: A carrier for pharmaceuticals and a scaffold for cell interactions,” Current Topics in Medicinal Chemistry, vol. 15, no. 4, pp. 309–327, 2015. View at Publisher · View at Google Scholar
  • Peng Huang, Chao Ma, Peng Xu, Kai Guo, Abai Xu, and Chunxiao Liu, “Efficacy of intravesical Bacillus Calmette-Guerin therapy against tumor immune escape in an orthotopic model of bladder cancer,” Experimental And Therapeutic Medicine, vol. 9, no. 1, pp. 162–166, 2015. View at Publisher · View at Google Scholar
  • Nathan A. Brooks, and Michael A. O'Donnell, “Treatment options in non-muscle-invasive bladder cancer after BCG failure,” Indian Journal of Urology, vol. 31, no. 4, pp. 312–319, 2015. View at Publisher · View at Google Scholar
  • Monali Vasekar, David Degraff, and Monika Joshi, “Immunotherapy in bladder cancer,” Current Molecular Pharmacology, vol. 9, no. 3, pp. 242–251, 2016. View at Publisher · View at Google Scholar
  • Patrick Vianna Garcia, Fábio Rodrigues Ferreira Seiva, Amanda Pocol Carniato, Wilson de Mello Júnior, Nelson Duran, Alda Maria Macedo, Alexandre Gabarra de Oliveira, Rok Romih, Iseu da Silva Nunes, Odilon da Silva Nunes, and Wagner José Fávaro, “Increased toll-like receptors and p53 levels regulate apoptosis and angiogenesis in non-muscle invasive bladder cancer: mechanism of action of P-MAPA biological response modifier,” BMC Cancer, vol. 16, no. 1, 2016. View at Publisher · View at Google Scholar
  • Gopitkumar Shah, Guangjian Zhang, Fanghong Chen, Yanli Cao, Balaraman Kalyanaraman, and William A. See, “The Dose-Response Relationship of bacillus Calmette-Guerin and Urothelial Carcinoma Cell Biology,” Journal Of Urology, vol. 195, no. 6, pp. 1903–1910, 2016. View at Publisher · View at Google Scholar
  • Anna Majewska, Witold Lasek, Mariola Kuczer, and Grazyna Mlynarczyk, “Inhibitory Effect of Alloferons in Combination with Human Lymphocytes on Human Herpesvirus 1 (HHV-1) Replication In Vitro,” International Journal Of Peptide Research And Therapeutics, vol. 22, no. 2, pp. 255–261, 2016. View at Publisher · View at Google Scholar
  • Sam J. Brancato, Piyush K. Agarwal, and Mahir Maruf, “Nonmuscle invasive bladder cancer: a primer on immunotherapy,” Cancer Biology and Medicine, vol. 13, no. 2, pp. 194–205, 2016. View at Publisher · View at Google Scholar
  • A. Korniluk, O. Koper, H. Kemona, and V. Dymicka-Piekarska, “From inflammation to cancer,” Irish Journal of Medical Science (1971 -), 2016. View at Publisher · View at Google Scholar
  • Amanda J. Vandeveer, Jonathan K. Fallon, Robert Tighe, Helen Sabzevari, Jeffrey Schlom, and John W. Greiner, “Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor,” Cancer Immunology Research, vol. 4, no. 5, pp. 452–462, 2016. View at Publisher · View at Google Scholar
  • Federico Garrido, Natalia Aptsiauri, Elien M Doorduijn, Angel M Garcia Lora, and Thorbald van Hall, “The urgent need to recover MHC class I in cancers for effective immunotherapy,” Current Opinion in Immunology, vol. 39, pp. 44–51, 2016. View at Publisher · View at Google Scholar
  • Keitaro Iida, Taku Naiki, Noriyasu Kawai, Toshiki Etani, Ryosuke Ando, Yosuke Ikegami, Takehiko Okamura, Hiroki Kubota, Atsushi Okada, Kenjiro Kohri, and Takahiro Yasui, “Bacillus Calmette-Guerin therapy after the second transurethral resection significantly decreases recurrence in patients with new onset high-grade T1 bladder cancer,” BMC Urology, vol. 16, no. 1, 2016. View at Publisher · View at Google Scholar
  • Sean G Smith, and David A Zaharoff, “Future directions in bladder cancer immunotherapy: towards adaptive immunity,” Immunotherapy, 2016. View at Publisher · View at Google Scholar
  • Subin Jin, Young Mi Whang, and In Ho Chang, “Recombinant Bacille Calmette–Guérin for Immunotherapy in Nonmuscle Invasive Bladder Cancer,” The Korean Journal of Urological Oncology, vol. 14, no. 3, pp. 109–117, 2016. View at Publisher · View at Google Scholar
  • Sonia Domingos-Pereira, Valérie Cesson, Mathieu Chevalier, Laurent Derré, Patrice Jichlinski, and Denise Nardelli-Haefliger, “Preclinical efficacy and safety of the Ty21a vaccine strain for intravesical immunotherapy of non-muscle-invasive bladder cancer,” OncoImmunology, pp. 00–00, 2016. View at Publisher · View at Google Scholar
  • H. Barton Grossman, Donald L. Lamm, Ashish M. Kamat, Stephen Keefe, John A. Taylor, and Molly A. Ingersoll, “Innovation in Bladder Cancer Immunotherapy,” Journal of Immunotherapy, vol. 39, no. 8, pp. 291–297, 2016. View at Publisher · View at Google Scholar
  • Ilias Elmouki, and Smahane Saadi, “Quadratic and linear controls developing an optimal treatment for the use of BCG immunotherapy in superficial bladder cancer,” Optimal Control Applications & Methods, vol. 37, no. 1, pp. 176–189, 2016. View at Publisher · View at Google Scholar
  • Queila Cristina Dias, Iseu da Silva Nunes, Patrick Vianna Garcia, and Wagner José Fávaro, “Potential therapeutic strategies for non - muscle invasive bladder cancer based on association of intravesical immunotherapy with P-MAPA and systemic administration of cisplatin and doxorubicin,” International Braz J Urol, vol. 42, no. 5, pp. 942–954, 2016. View at Publisher · View at Google Scholar
  • Thenappan Chandrasekar, and Christopher P. Evans, “Autophagy and urothelial carcinoma of the bladder: A review,” Investigative and Clinical Urology, vol. 57, no. Suppl1, pp. S89, 2016. View at Publisher · View at Google Scholar
  • T. N. Nissen, N. M. Birk, B. A. Blok, R. J. W. Arts, A. Andersen, J. Kjærgaard, L. M. Thøstesen, T. Hoffmann, D. L. Jeppesen, S. D. Nielsen, P.-E. Kofoed, L. G. Stensballe, P. Aaby, M. Ruhwald, M. G. Netea, C. S. Benn, and O. Pryds, “Bacillus Calmette-Guérin vaccination at birth and in vitro cytokine responses to non-specific stimulation. A randomized clinical trial,” European Journal of Clinical Microbiology & Infectious Diseases, 2017. View at Publisher · View at Google Scholar
  • Alexander R. L. Robinson, Rajeswari Radhakrishnan, Robert Horvath, and Sushil Pandey, “ A case of disseminated Mycobacterium bovis 2 years post-intravesicular Bacillus Calmette-Guérin therapy for superficial urinary bladder cancer ,” Internal Medicine Journal, vol. 47, no. 7, pp. 820–823, 2017. View at Publisher · View at Google Scholar
  • Daniel P. Petrylak, “Immunotherapy: The Wave of the Future in Bladder Cancer?,” Clinical Genitourinary Cancer, vol. 15, no. 3, pp. S3–S17, 2017. View at Publisher · View at Google Scholar
  • Shunta Hori, Makito Miyake, Yoshihiro Tatsumi, Sayuri Onishi, Yosuke Morizawa, Yasushi Nakai, Nobumichi Tanaka, and Kiyohide Fujimoto, “Topical and systemic immunoreaction triggered by intravesical chemotherapy in an N-butyl-N-(4-hydroxybutyl) nitorosamine induced bladder cancer mouse model,” PLoS ONE, vol. 12, no. 4, 2017. View at Publisher · View at Google Scholar
  • Davide Valentini, Martin Rao, Lalit Rane, Sayma Rahman, Rebecca Axelsson-Robertson, Rainer Heuchel, Matthias Löhr, Daniel Hoft, Susanna Brighenti, Alimuddin Zumla, and Markus Maeurer, “Peptide microarray-based characterization of antibody responses to host proteins after bacille Calmette–Guérin vaccination,” International Journal of Infectious Diseases, 2017. View at Publisher · View at Google Scholar
  • Karan Seegobin, Satish Maharaj, Cherisse Baldeo, Carmen Isache, Bharatsinh Gharia, and Lara Zuberi, “Mycobacteria Bovis osteomyelitis following intravesical BCG for bladder cancer,” IDCases, vol. 10, pp. 75–78, 2017. View at Publisher · View at Google Scholar
  • Farouk Tijjani Saad, Evren Hincal, and Bilgen Kaymakamzade, “Dynamics of Immune Checkpoints, Immune System, and BCG in the Treatment of Superficial Bladder Cancer,” Computational and Mathematical Methods in Medicine, vol. 2017, pp. 1–9, 2017. View at Publisher · View at Google Scholar